Norton Rose Fulbright advises NOVENTI on the sale of its subsidiary NOVENTI Care to Volaris Group

Global law firm Norton Rose Fulbright has advised NOVENTI Health SE, one of the leading financial and IT service providers in the healthcare sector, on the sale of its subsidiary NOVENTI Care to Volaris Group.

NOVENTI Care is a software company that has specialised in the development and distribution of care software for over 30 years. For NOVENTI, the sale is a decisive step in the realignment and stronger focus on its own core business announced in January 2023. The Volaris Group is a buy-and-hold acquirer of software companies in various industries with the aim of strengthening the portfolio companies in their respective markets and supporting them in their growth. NOVENTI Care will continue to develop its care software under the new ownership of the Volaris Group.

The transaction comprised the sale of all shares in NOVENTI Care GmbH as well as the conclusion of various ancillary agreements, including on a transfer of employees and operations, software development and transitional services.

NOVENTI was advised on the transaction by a Norton Rose Fulbright team led by Hamburg partner Dr Heiko Bertelmann (Corporate / M&A) and counsel Dr Malte Ingwersen (Corporate / M&A, Hamburg). Heiko Bertelmann also heads the firm's Life Sciences and Healthcare practice in Germany and Europe.

In addition to Dr Heiko Bertelmann and Dr Malte Ingwersen, the transaction was advised by partner Dr Sylwia Maria Bea-Pulverich, associate Lorenz Scholtis, associate Anna-Maria Baorda (all restructuring, Frankfurt), partner Dr Christopher Ritzer, Counsel Dr Ingemar Kartheuser (both IT/IP/Data Protection, Frankfurt), Partner Claudia Posluschny, Associate Christina Wiesel (both employment law, Munich), Partner Daniel Marschollek, Counsel Manuel Merling (both IP, Frankfurt), Partner Dr Bernhard Fiedler (Banking/Finance, Frankfurt) and Associate Marcel Gießler (Corporate / M&A, Hamburg).

Norton Rose Fulbright's German team has already advised NOVENTI on previous transactions, most recently in January 2023 on a successful refinancing of its 1.4 billion euro syndicated loan. "The continuation of our successful cooperation with NOVENTI is a very strong and important vote of confidence for us as a law firm. By concluding this further important transaction, we were able to make a significant contribution to strengthening our client's market position," says Frankfurt partner Dr Sylwia Maria Bea-Pulverich, who has been advising the company since the beginning of the collaboration.

The Life Sciences & Healthcare team at Norton Rose Fulbright offers pharmaceutical and medical device companies, healthcare service providers and investors comprehensive advice in all relevant areas of law, in particular in the fields of IP/IT and data protection, regulatory and compliance as well as M&A. In addition to many years of industry expertise, the broad-based team benefits from the firm's global network and the national and international integration of the individual practice groups and jurisdictions.

The Volaris Group was advised on the transaction by a team from Taylor Wessing led by Hamburg partner Dr Jan Riebeling.